712-08-3

Basic information

• Product Name: 5-fluoro-alpha-methyltryptamine
• Synonyms: 5-fluoro-alpha-methyltryptamine;1-(5-fluoro-1H-indol-3-yl)propan-2-amine
• CAS NO: 712-08-3
• Molecular Formula: C₁₁H₁₃FN₂
• Molecular Weight: 192.24
• Mol File: 712-08-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 348°C at 760 mmHg
• Flash Point: 164.3°C
• Appearance: /
• Vapor Pressure: 5.17E-05mmHg at 25°C
• CAS DataBase Reference: 5-fluoro-alpha-methyltryptamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-alpha-methyltryptamine(712-08-3)
• EPA Substance Registry System: 5-fluoro-alpha-methyltryptamine(712-08-3)

Safety Data

• Hazardous Substances Data: 712-08-3(Hazardous Substances Data)

Usage

General Description

5-Fluoro-alpha-methyltryptamine, also known as 5-MeO-AMT, is a synthetic chemical compound that belongs to the tryptamine class. It is a potent psychedelic and hallucinogenic drug that acts as a serotonin-norepinephrine-dopamine releasing agent. 5-MeO-AMT has been associated with a range of psychoactive effects, including visual and auditory hallucinations, sensory distortion, and intense emotional experiences. It has also been reported to produce stimulant-like effects, such as increased energy and euphoria. Due to its potential for misuse and abuse, 5-MeO-AMT is classified as a controlled substance in many countries and is illegal to manufacture, possess, or distribute without proper authorization. Its effects on human health and safety are not well studied, and the use of 5-MeO-AMT may pose significant risks to users, including potential adverse effects on mental and physical health.

InChI:InChI=1/C11H13FN2.ClH/c1-7(13)4-8-6-14-11-3-2-9(12)5-10(8)11;/h2-3,5-7,14H,4,13H2,1H3;1H

Upstream product

• 1895-00-7 5-fluoro-3-(2-nitroprop-1-en-1-yl)-1H-indole 
• 2338-71-8 5-fluoro-1H-indole-3-carbaldehyde 
• 1895-00-7 5-fluoro-3-[(1Z)-2-nitroprop-1-en-1-yl]-1H-indole 
• 399-52-0 5-fluoro-1H-indole 

Relevant articles and documents

SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF

The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer).Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Synthesis and structureactivity relationship of novel conformationally restricted analogues of serotonin as 5-HT6 receptor ligands

5-Hydroxytryptamine 6 receptors (5-HT6R) are being perceived as the possible target for treatment of cognitive disorders as well as obesity. The present article deals with the design, synthesis, in vitro binding and structureactivity relationship of a novel series of tetracyclic tryptamines with the rigidized N-arylsulphonyl, N-arylcarbonyl and N-benzyl substituents as 5-HT6 receptor ligands. The chiral sulphonyl derivatives 15a and 17a showed high affinity at 5-HT6R with the Ki of 23.4 and 20.5nM, respectively. The lead compound from the series 15a has acceptable ADME properties, adequate brain penetration and is active in animal models of cognition like Novel Object Recognition Task (NORT) and water maze.

α-Methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands

α-Methyltryptamine sulfonamides were identified as human glucocorticoid receptor (hGR) ligands in an ultra high throughput screening (UHTS) campaign. Described will be the hit-to-lead activities, including parallel and single point analog synthesis to map the scaffold. Ligands were identified that exhibited 30 nM binding to hGR. The SAR and selectivity of these compounds will be discussed.